M2S, Inc has boosted its core capabilities in clinical trial image management by acquiring fellow US specialist DXA Resource Group (DRG) for an undisclosed sum.
Founded in 2002 and based in Westborough, Massachusetts, DRG is a clinical trials service company focused on cost-effective quality assurance as well as data and project management for clinical trials involving Dual X-ray Absorptiometry (DXA) measurements.
As M2S explained, DXA is a low-dose (one tenth of a traditional X-ray) imaging modality that measures bone mineral density and body mass composition. The technology is increasingly used in clinical trials to assess the safety and effectiveness of drugs for indications such as osteoporosis, HIV, obesity, growth hormone deficiency, endometrioisis, fibroids and Gaucher’s disease.
M2S itself is a global provider of image management services for biopharmaceutical and medical device trials, operating out of headquarters in West Lebanon, New Hampshire.
In addition to its Clinical Trials Imaging division, the company runs an Endovascular Imaging division using its proprietary 3D image segmentation and modelling services to help surgeons and researchers in pre- and post-operative evaluations of stent graft placement; and a Data Registries division, which creates and maintains customised online registries allowing clients to gather, manage, mine and store critical medical data and images.
“DRG has integrated quality service with imaging data technology, which exactly fits into the M2S mission and clinical trials image management service offering,” said the company’s chief executive officer, Wes Chapman. “The addition of DRG allows M2S to further expand our capabilities and therapeutic expertise, and meet the growing demand for image management services worldwide.”
